197 related articles for article (PubMed ID: 15728918)
1. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.
Peláez T; Alcalá L; Alonso R; Martín-López A; García-Arias V; Marín M; Bouza E
Antimicrob Agents Chemother; 2005 Mar; 49(3):1157-9. PubMed ID: 15728918
[TBL] [Abstract][Full Text] [Related]
2. Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model.
Kraus CN; Lyerly MW; Carman RJ
Antimicrob Agents Chemother; 2015 May; 59(5):2525-30. PubMed ID: 25691641
[TBL] [Abstract][Full Text] [Related]
3. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.
O'Connor R; Baines SD; Freeman J; Wilcox MH
J Antimicrob Chemother; 2008 Oct; 62(4):762-5. PubMed ID: 18606787
[TBL] [Abstract][Full Text] [Related]
4. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibilities of Clostridium difficile isolated in Japan.
Kunishima H; Chiba J; Saito M; Honda Y; Kaku M
J Infect Chemother; 2013 Apr; 19(2):360-2. PubMed ID: 23338015
[TBL] [Abstract][Full Text] [Related]
6. [Assessment of susceptibility to metronidazole and vancomycin of Clostridium difficile strains isolated between 1998-2002].
Pituch H; Obuch-Woszczatyński P; Glinka D; Łazińska B; Meisel-Mikołajczyk F; Łuczak M
Med Dosw Mikrobiol; 2003; 55(3):253-8. PubMed ID: 14702667
[TBL] [Abstract][Full Text] [Related]
7. Antibacterial activity of teicoplanin against Clostridium difficile.
Wongwanich S; Kusum M; Phan-Urai R
Southeast Asian J Trop Med Public Health; 1996 Sep; 27(3):606-9. PubMed ID: 9185278
[TBL] [Abstract][Full Text] [Related]
8. The emergence of metronidazole and vancomycin reduced susceptibility in Clostridium difficile isolates in Iran.
Kouhsari E; Douraghi M; Krutova M; Fakhre Yaseri H; Talebi M; Baseri Z; Moqarabzadeh V; Sholeh M; Amirmozafari N
J Glob Antimicrob Resist; 2019 Sep; 18():28-33. PubMed ID: 30703583
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility of Clostridium difficile isolates in Israel.
Tkhawkho L; Nitzan O; Pastukh N; Brodsky D; Jackson K; Peretz A
J Glob Antimicrob Resist; 2017 Sep; 10():161-164. PubMed ID: 28729205
[TBL] [Abstract][Full Text] [Related]
10. Bactericidal activity of telavancin, vancomycin and metronidazole against Clostridium difficile.
Goldstein EJ; Citron DM; Tyrrell KL; Warren YA
Anaerobe; 2010 Jun; 16(3):220-2. PubMed ID: 20044011
[TBL] [Abstract][Full Text] [Related]
11. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.
Wong SS; Woo PC; Luk WK; Yuen KY
Diagn Microbiol Infect Dis; 1999 May; 34(1):1-6. PubMed ID: 10342100
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
[TBL] [Abstract][Full Text] [Related]
14. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
[TBL] [Abstract][Full Text] [Related]
15. A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole.
Adler A; Miller-Roll T; Bradenstein R; Block C; Mendelson B; Parizade M; Paitan Y; Schwartz D; Peled N; Carmeli Y; Schwaber MJ
Diagn Microbiol Infect Dis; 2015 Sep; 83(1):21-4. PubMed ID: 26116225
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization and antimicrobial susceptibilities of Clostridium difficile clinical isolates from Victoria, Australia.
Mackin KE; Elliott B; Kotsanas D; Howden BP; Carter GP; Korman TM; Riley TV; Rood JI; Jenkin GA; Lyras D
Anaerobe; 2015 Aug; 34():80-3. PubMed ID: 25944720
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.
Reigadas E; Alcalá L; Marín M; Pelaéz T; Martin A; Iglesias C; Bouza E
J Antimicrob Chemother; 2015 Aug; 70(8):2311-5. PubMed ID: 25876881
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of Clostridium difficile by E test.
Cheng SH; Chu FY; Lo SH; Lu JJ
J Microbiol Immunol Infect; 1999 Jun; 32(2):116-20. PubMed ID: 11561576
[TBL] [Abstract][Full Text] [Related]
19. Highly antibiotic-resistant Clostridium difficile isolates from Iranian patients.
Baghani A; Ghourchian S; Aliramezani A; Yaseri M; Mesdaghinia A; Douraghi M
J Appl Microbiol; 2018 Nov; 125(5):1518-1525. PubMed ID: 29957893
[TBL] [Abstract][Full Text] [Related]
20. [Antimicrobial susceptibility of Clostridium difficile clinical isolates collected from 2001 to 2007 in a French university hospital].
Cattoir V; Ould-Hocine ZF; Legrand P
Pathol Biol (Paris); 2008; 56(7-8):407-11. PubMed ID: 18845403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
